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Edited by Richard MarasAbstract Cisplatin is a key agent in combination chemotherapy
for various types of solid tumor. We now show that cisplatin acti-
vates signaling by the epidermal growth factor receptor (EGFR)
by inducing cleavage of heparin-binding epidermal growth fac-
tor-like growth factor (HB-EGF). Matuzumab, a monoclonal
antibody to EGFR, inhibited cisplatin-induced EGFR signaling,
likely through competition with the soluble form of HB-EGF for
binding to EGFR. Matuzumab enhanced the antitumor eﬀect of
cisplatin in nude mice harboring human non-small cell lung can-
cer xenografts. Our ﬁndings shed light on the mechanism by
which monoclonal antibodies to EGFR might augment the eﬃ-
cacy of cisplatin.
Crown Copyright  2008 Published by Elsevier B.V. on behalf of
the Federation of European Biochemical Societies. All rights
reserved.
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Cisplatin is a key component of combination chemotherapy
for various types of solid tumor, but its eﬀectiveness is limited
by the development of chemoresistance [1]. Several nonphysio-
logical stimuli that induce cellular stress, such as hyperosmo-
larity, wounding, UV or c-radiation, reactive oxygen species,
and chemotherapeutic agents, trigger activation of the epider-
mal growth factor receptor (EGFR) [2–11]. Ligand binding to
EGFR induces receptor dimerization and activation of the
receptor kinase, triggering intracellular signaling pathways
such as those mediated by the protein kinases Akt or extracel-
lular signal-regulated kinase (Erk), which play fundamental
roles in the control of numerous cellular processes such as
growth, proliferation, and survival [12–18]. EGFR signaling
pathways activated by cellular stressors are thus of clinical
interest because of their potential role in tumor resistance to
chemotherapy [2–11]. The eﬀects of cisplatin on EGFR signal-
ing pathways have remained unclear, but the potential role ofAbbreviations: EGF, epidermal growth factor; EGFR, EGF receptor;
mAb, monoclonal antibody; NSCLC, non-small cell lung cancer; HB-
EGF, heparin-binding EGF-like growth factor; HRP, horseradish
peroxidase; TUNEL, terminal deoxynucleotidyl transferase-mediated
dUTP nick-end labeling
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doi:10.1016/j.febslet.2008.11.010these pathways in cisplatin resistance makes it important to
examine whether EGFR inhibitors might enhance the antitu-
mor eﬀects of this drug [8,9].
We have now examined the molecular mechanism of cis-
platin-induced activation of EGFR and the eﬀects of this drug
on downstream signaling pathways. We also examined the ef-
fects of matuzumab (EMD72000, humanized mouse immuno-
globulin G1), a monoclonal antibody (mAb) to EGFR [19], on
cisplatin-dependent EGFR signaling. Finally, the antitumor
eﬀect of matuzumab combined with cisplatin was evaluated
in order to provide insight into the mechanism by which
anti-EGFR mAbs might augment the eﬃcacy of cisplatin.2. Materials and methods
2.1. Cell culture and reagents
The human non-small cell lung cancer (NSCLC) cell lines NCI-H292
(H292), NCI-H460 (H460), and A549 were obtained and cultured as
previously described [20]. Matuzumab and geﬁtinib were also obtained
as previously described [19]; GM6001 was from Calbiochem (La Jolla,
CA); cisplatin, CRM197, and epidermal growth factor (EGF) were
from Sigma (St. Louis, MO); and heparin-binding EGF-like growth
factor (HB-EGF) was from R&D Systems (Minneapolis, MN).
2.2. Immunoblot analysis
Immunoblot analysis was performed as described previously [20].
Primary antibodies to the Tyr845-phosphorylated form of EGFR, to
EGFR, to phosphorylated Erk, to Erk, to phosphorylated Akt, and
to Akt as well as horseradish peroxidase (HRP)-conjugated goat anti-
bodies to mouse or rabbit immunoglobulin G were obtained as de-
scribed previously [20]. Primary antibodies to the intracellular
COOH-terminal domain of HB-EGF and HRP-conjugated donkey
antibodies to goat immunoglobulin G were from Santa Cruz Biotech-
nology (Santa Cruz, CA).
2.3. Assessment of tumor growth inhibition in vivo
Tumor cells (2 · 106) were injected subcutaneously into the ﬂank of
7-week-old female athymic nude mice. The mice were divided into four
treatment groups of seven or eight animals: those treated over 2 weeks
by intraperitoneal injection of vehicle, matuzumab (0.05 mg, twice per
week), cisplatin (6 mg/kg of body weight, twice per week), or both mat-
uzumab and cisplatin. Treatment was initiated when tumors in each
group achieved an average volume of 200 mm3, with tumor volume
being determined twice weekly for 41 days after the onset of treatment
from caliper measurement of tumor length (L) and width (W) accord-
ing to the formula LW2/2.
2.4. Ki67 index
Tumors were removed from some animals 14 days after treatment
initiation and were stained with a mouse mAb to human Ki67 (clone
MIB-1; Dako, Carpinteria, CA), as previously described [21]. Thelf of theFederationofEuropeanBiochemical Societies.All rights reserved.
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scoring at least 300 tumor cells in each of 10 well-preserved ﬁelds of
each tumor at a magniﬁcation of ·200 (CX41 light microscope; Olym-
pus, Tokyo, Japan).
2.5. TUNEL staining
Terminal deoxynucleotidyl transferase-mediated dUTP nick-end
labeling (TUNEL) analysis of tumor sections was performed as de-Fig. 1. Cisplatin-induced activation of EGFR and of downstream signaling p
or H460 (C) cells were incubated for the indicated times in the absence or pre
immunoblot analysis with antibodies to the Tyr845-phosphorylated form of E
well as with antibodies to total forms of these proteins.
Fig. 2. Cisplatin-induced HB-EGF cleavage and its role in activation of EGF
incubated for the indicated times in the presence of cisplatin (100 lM). Cell ly
intracellular COOH-terminal domain of HB-EGF. The positions of molecular
and to the cleaved tail fragment (right) are indicated. (B) Serum-deprived H29
absence or presence of GM6001 (10 lM) for 12 h. Cell lysates were then subj
were incubated with EGF (100 ng/ml) for 15 min as a positive control or wit
CRM197 (10 lg/ml) for 12 h. Cell lysates were then subjected to immunoblo
Erk.scribed previously [22]. The number of apoptotic cells in each of 10
ﬁelds (·200) per tumor was determined with a light microscope
(CX41, Olympus).
2.6. Statistical analysis
Quantitative data are presented as means ± S.D. and were compared
among groups by one-way analysis of variance followed by Tukeys
multiple comparison test. A P value of <0.05 was consideredathways mediated by Akt or Erk. Serum-deprived H292 (A), A549 (B),
sence of cisplatin (CDDP, 100 lM). Cell lysates were then subjected to
GFR (pEGFR), to phosphorylated Akt, or to phosphorylated Erk as
R signaling pathways by cisplatin. (A) Serum-deprived H292 cells were
sates were then subjected to immunoblot analysis with antibodies to the
size standards (left) as well as of bands corresponding to pro-HB-EGF
2 cells were incubated alone (control) or with cisplatin (100 lM) in the
ected to immunoblot analysis as in (A). (C) Serum-deprived H292 cells
h cisplatin (100 lM) in the absence or presence of GM6001 (10 lM) or
t analysis with antibodies to phosphorylated or total forms of Akt or
T. Yoshida et al. / FEBS Letters 582 (2008) 4125–4130 4127statistically signiﬁcant. Statistical analysis was performed with Graph-
Pad Prism version 5.00 for Windows (GraphPad Software, San Diego,
CA).3. Results and discussion
3.1. Cisplatin activates EGFR as well as downstream Akt and
Erk signaling pathways
Cellular stress induced by several chemotherapeutic agents
or c-radiation triggers the activation of EGFR signaling path-
ways, with this eﬀect being thought to play an important role
in resistance to chemotherapy or radiotherapy [6–11]. We
examined the eﬀects of cisplatin on EGFR and downstream
signaling pathways mediated by Akt or Erk in human NSCLC
cell lines (H292, A549, H460). Cisplatin induced the phosphor-
ylation of EGFR, Akt, and Erk in a time-dependent manner,
without aﬀecting the total amounts of these proteins, in all
three cell lines (Fig. 1). These results thus showed that cisplatinFig. 3. Inhibition by matuzumab of EGFR signaling induced by HB-EGF or
in the absence or presence of matuzumab (200 nM) and then for 15 min in t
were then subjected to immunoblot analysis with antibodies to phosphorylate
(C), or H460 (D) cells were incubated with EGF (100 ng/ml) for 15 min as a p
matuzumab (200 nM) or geﬁtinib (10 lM) for 12 h. Cell lysates were then suactivates EGFR and downstream signaling pathways mediated
by Akt or Erk.
3.2. Cisplatin activates EGFR signaling pathways by inducing
the cleavage of HB-EGF
HB-EGF is a membrane-bound EGFR ligand that activates
EGFR after its release from the membrane in response to cel-
lular stress [3,5,23–25]. To determine whether HB-EGF con-
tributes to cisplatin-induced EGFR signaling, we examined
the possible eﬀect of cisplatin on cleavage of the membrane-
bound pro-form of HB-EGF in H292 cells. Cisplatin induced
a time-dependent decrease in the amount of pro-HB-EGF
and a consequent increase in the amount of a COOH-terminal
fragment of this protein referred to as the ‘‘tail fragment’’
(Fig. 2A). These eﬀects of cisplatin were inhibited by
GM6001 (Fig. 2B), a potent inhibitor of matrix metallopro-
teinases responsible for HB-EGF cleavage [23,24], suggesting
that cisplatin induces metalloproteinase-mediated cleavage of
the ectodomain of HB-EGF and its release from the cell sur-by cisplatin. (A) Serum-deprived H292 cells were incubated ﬁrst for 2 h
he additional absence or presence of HB-EGF (10 ng/ml). Cell lysates
d or total forms of Akt or Erk. (B–D) Serum-deprived H292 (B), A549
ositive control or with cisplatin (100 lM) in the absence or presence of
bjected to immunoblot analysis as in (A).
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cisplatin (Fig. 2C), implicating HB-EGF cleavage in cis-
platin-induced EGFR signaling. To explore further whether
cisplatin-induced EGFR signaling is dependent on HB-EGF
activity, we examined the eﬀect of CRM197, a nontoxic mu-
tant form of diphtheria toxin that binds speciﬁcally to and neu-
tralizes HB-EGF, which has also been identiﬁed as a
diphtheria toxin receptor [26]. CRM197 completely inhibited
the activation of Akt and Erk by cisplatin (Fig. 2C), suggesting
that cisplatin promotes EGFR signaling by inducing the cleav-
age of HB-EGF. Consistent with this notion, the time course
of cisplatin-induced activation of EGFR signaling (Fig. 1A)
was similar to that of cisplatin-induced release of HB-EGF
from the cell surface (Fig. 2A).
Cisplatin has previously been shown to increase the amount
of HB-EGF mRNA in various types of cancer cells [7], and
expression of the HB-EGF gene was found to be increased
in cisplatin-resistant cancer [27]. The chemotherapeutic drugs
SN38, doxorubicin, and imatinib also induce EGFR signaling
and subsequent chemoresistance through metalloproteinase-
dependent cleavage of HB-EGF [7,10]. It is possible thatFig. 4. Enhancement by matuzumab of the antitumor eﬀect of cisplatin in v
treated with a single intraperitoneal dose of matuzumab (0.05 mg) or cisplatin
14 days. Tumor volume was determined at the indicated times after the onset
tumor xenografts 14 days after the initiation of treatment as in (A). (C) Quan
(·200) in H292 tumor xenografts 14 days after the initiation of treatment
**P < 0.05 versus control or each agent alone.EGFR signaling resulting from metalloproteinase-mediated
cleavage of HB-EGF represents a common mechanism of cel-
lular resistance to various chemotherapeutic agents.
3.3. Eﬀects of matuzumab on cisplatin-induced EGFR signaling
The clinical eﬃcacy of treatment with anti-EGFR mAbs has
been thought to be due to their prevention of ligand binding to
EGFR [28,29]. We hypothesized that anti-EGFR mAbs might
inhibit cisplatin-induced EGFR signaling by blocking the
binding of the released ectodomain of HB-EGF to EGFR.
To test whether anti-EGFR mAbs inhibit EGFR signaling in-
duced by HB-EGF, we examined the eﬀects of the humanized
anti-EGFR mAb matuzumab. Matuzumab indeed prevented
the activation of Akt and Erk by HB-EGF (Fig. 3A), indicat-
ing that this mAb inhibits HB-EGF–dependent EGFR signal-
ing. We next examined the eﬀect of matuzumab on cisplatin-
induced EGFR signal transduction. The activation of EGFR
downstream signaling by cisplatin was abolished by geﬁtinib
in H292, A549, and H460 cells (Fig. 3B–D), suggesting that
cisplatin-induced EGFR signaling requires the tyrosine kinase
activity of EGFR. Matuzumab also markedly inhibitedivo. (A) Nude mice harboring H292 tumor xenografts (200 mm3) were
(6 mg/kg), with both agents, or with vehicle (control) twice a week for
of treatment. (B) The Ki67 index was determined from sections of H292
titation by TUNEL staining of the number of apoptotic cells per ﬁeld
as in (A). Data in (A–C) are means ± S.D. *P < 0.05 versus control;
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(Fig. 3B–D). These results thus suggested that matuzumab
blocks cisplatin-induced EGFR signaling through inhibition
of HB-EGF-dependent activation of EGFR.
Matuzumab exerts its antitumor eﬀect both by competition
with EGF for binding to EGFR and by blockade of the EGFR
turnover that is important for activation of downstream sig-
naling pathways mediated by Akt or Erk [19,28,29]. The solu-
ble form of HB-EGF includes the EGF-like domain, a
common structure in members of the EGF family of proteins
that consists of 40–45 amino acids and contains six cysteine
residues, but it binds not only to EGFR but also to ErbB4,
whereas EGF binds speciﬁcally to EGFR [23–25]. The corre-
sponding binding site of EGFR or the ligand function of
HB-EGF may therefore diﬀer from those for EGF. Neverthe-
less, we have now shown that matuzumab also inhibits the
activation of EGFR signaling by both HB-EGF and cisplatin.
3.4. Matuzumab enhances the antitumor action of cisplatin in
H292 xenografts
If cisplatin-induced EGFR signaling plays an important role
in the development of cisplatin resistance, matuzumab might
be expected to enhance the antitumor eﬀect of cisplatin by
inhibiting such signaling. We therefore determined the eﬃcacy
of combined treatment with matuzumab and cisplatin in nude
mice with solid tumors formed by H292 cells injected into the
ﬂank. Combination therapy with matuzumab and cisplatin
inhibited tumor growth to a signiﬁcantly greater extent than
did treatment with matuzumab or cisplatin alone (Fig. 4A).
Tumors treated with the combination of matuzumab and
cisplatin also manifested both a signiﬁcantly smaller Ki67 in-
dex (Fig. 4B), a marker of cell proliferation, and a signiﬁcantly
greater proportion of apoptotic cells (Fig. 4C), compared with
tumors treated with either agent alone. Matuzumab alone or in
combination with cytotoxic agents was previously shown to in-
hibit Akt or Erk phosphorylation in human tissue samples or
human xenografts in nude mice [30–34]. The combination of
matuzumab and cisplatin likely reduced the Ki67 index in
the present study because matuzumab blocked the cisplatin-in-
duced activation of Erk, which is important for cancer cell pro-
liferation as a component of the Ras-MEK-Erk signaling
pathway [17,18]. The increase in the number of apoptotic cells
in tumors treated with both matuzumab and cisplatin likely re-
sulted from inhibition by matuzumab of the cisplatin-induced
activation of Akt, which contributes to antiapoptotic signaling
through several pathways [15,16]. Our data thus indicate that
matuzumab enhanced the antitumor eﬀect of cisplatin, with
the combination treatment inhibiting tumor cell proliferation
and inducing apoptosis to a greater extent than treatment with
either agent alone. Our data showing that geﬁtinib also
blocked cisplatin-induced activation of Akt and Erk may ex-
plain the previous observation that the growth-inhibitory ac-
tion of cisplatin in A549 tumors was increased fourfold in
combination with geﬁtinib [35]. Our ﬁndings suggest the
importance of EGFR signaling in the development of chemo-
resistance to cisplatin, and they provide insight into the mech-
anism by which anti-EGFR mAbs might augment the eﬃcacy
of cisplatin. Clinical studies of the therapeutic eﬃcacy of mat-
uzumab combined with cisplatin are thus warranted.
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